Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-α) and their relation to premature atherosclerosis in β-thalassemia children

Hematology

Volumn 20, Issue 4, 2015, Pages 228-238

  Ragab, Seham M ^a   Safan, Manal A ^a   Obeid, Osama M ^a   Sherief, Asmaa S ^b  

^a MENOUFIA UNIVERSITY   (Egypt)

^b Shebeen El Kom Teaching Hospital   (Egypt)

Author keywords

Carotid intima media thickness (cIMT); Lp PLA2; Premature atherosclerosis; TNF ; Thalassemia

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; DEFERASIROX; DEFEROXAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TUMOR NECROSIS FACTOR ALPHA; LIPID; LIPOPROTEIN;

ADOLESCENT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BETA THALASSEMIA; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITIN BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; MALE; NEWBORN DISEASE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMPLICATION; PRESCHOOL CHILD;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; ATHEROSCLEROSIS; BETA-THALASSEMIA; CAROTID INTIMA-MEDIA THICKNESS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS; MALE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928544992     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845414Y.0000000180     Document Type: Article

References (68)

1. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135–46
2. Taher A, Isma’eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, et al. Prevalence of thromboembolic events among 8860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006; 96(4):488–91
3. Cheung YF, Chan GC, Ha SY. Arterial stiffness and endothelial function in patients with β-thalassemia major. Circulation 2002; 106(20):2561–6
4. Hahalis G, Kremastinos DT, Terzis G, Kalogeropoulos AP, Chrysanthopoulou A, Karakantza M, et al. Global vasomotor dysfunction and accelerated vascular aging in beta-thalassemia major. Atherosclerosis 2008;198(2):448–57
5. Taher A, Isma’eel H, Cappellini MD. Thalassemia intermedia; revisited. Blood Cells Mol Dis. 2006;37(1):12–20
6. Kyriakou DS, Alexandrakis MG, Kyriakou ES, Liapi D, Kourelis TV, Passam F, et al. Activated peripheral blood and endothelial cells in thalassemia patients. Ann Hematol. 2001; 80(10):577–83
7. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473(7347):317–25
8. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95
9. Tselepis AD, John Chapman M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 2002;3(4):57–68
10. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta. 2009;1791(5): 327–38
11. Girn HR, Orsi NM, Homer-Vanniasinkam S. An overview of cytokine interactions in atherosclerosis and implications for peripheral arterial disease. Vasc Med. 2007;12(4):299–309
12. Lorenz MW, von Kegler S, Steinmetz H, Markus HS, Sitzer M. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2006;37(1): 87–92
13. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intimamedia thickness: a systematic review and meta-analysis. Circulation 2007;115(4):459–67
14. Tantawy AA, Adly AA, El Maaty MG, Amin SA. Subclinical atherosclerosis in young beta-thalassemia major patients. Hemoglobin 2009;33(6):463–74
15. Akhlaghpoor S, Hoseini M, Jafarisepehr A. Association of iron overload based quantitative T2* MRI technique and carotid intima-media thickness in patients with beta-thalassemia: a cross-sectional study. BMC Cardiovasc Disord. 2010;10:62
16. Tselepis AD, Hahalis G, Tellis CC, Papavasiliou EC, Mylona PT, Kourakli A, et al. Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemia. J Lipid Res. 2010;51(11):3331–41
17. Hahalis G, Kalogeropoulos A, Terzis G, Tselepis AD, Kourakli A, Mylona P, et al. Premature atherosclerosis in non-transfusiondependent β-thalassemia intermedia. Cardiology. 2011;118(3): 159–63
18. Cheung YF, Chow PC, Chan GC, Ha SY. Carotid intima-media thickness is increased and related to arterial stiffening in patients with beta-thalassaemia major. Br J Haematol. 2006;135(5): 732–4
19. Dogan M, Citak EC. The evaluation of carotid intima-media thickness in children with beta-thalassaemia major. Cardiol Young 2012;22(1):79–83
20. Gursel O, Kurekci AE, Tascilar E, Ileri T, Altun D, Tapan S, et al. Premature atherosclerosis in children with β-thalassemia major. J Pediatr Hematol Oncol. 2012;34(8):630–4
21. Thalassaemia International Federation. Guidelines for the cinical management of thalassaemia. 2nd revised edition. Nicosia, Cyprus: Thalassaemia International Federation; 2008 [accessed 2011 Jun 21]. Available from: http://www.thalassaemia.org.cy/pdf/Guidelines_2nd_revised_edition_EN.pdf.
22. Mellouli F, El Borgi W, Kaabi H, Ben Hassen E, Sassi R, Hmida H, et al. [HFE gene mutations in Tunisian major beta-thalassemia and iron overload]. Transfus Clin Biol. 2006;13(6):353–7
23. Richmond W. Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem. 1973;19(12):1350–6
24. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28(10):2077–80
25. Lippi U, Graziani MS, Schinella M, Manzato F, Bazzani R. Determination of high density lipoprotein cholesterol in venous and capillary whole blood. J Lipid Res. 1988;29(1):112–5
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499–502
27. Margeirsdottir HD, Stensaeth KH, Larsen JR, Brunborg C, Dahl-Jørgensen K. Early signs of atherosclerosis in diabetic children on intensive insulin treatment: a population-based study. Diabetes Care 2010;33(9):2043–8
28. Toth PP. Subclinical atherosclerosis: what it is, what it means and what we can do about it. Int J Clin Pract. 2008;62(8): 1246–54
29. Hansen ME, Valentine RJ, McIntire DD, Myers SI, Chervu A, Clagett GP. Age-related differences in the distribution of peripheral atherosclerosis: when is atherosclerosis truly premature? Surgery 1995;118(5):834–9
30. Böhm B, Hartmann K, Buck M, Oberhoffer R. Sex differences of carotid intima-media thickness in healthy children and adolescents. Atherosclerosis 2009;206(2):458–63
31. Jourdan C, Wühl E, Litwin M, Fahr K, Trelewicz J, Jobs K, et al. Normative values for intima-media thickness and distensibility of large arteries in healthy adolescents. J Hypertens. 2005; 23(9):1707–15
32. de Arriba Muñoz A, Domínguez Cajal MM, Labarta Aizpún JI, Domínguez Cunchillos M, Mayayo Dehesa E, Ferrández Longás Á. [Carotid intima-media thickness; normal values from 4 years]. Nutr Hosp. 2013;28(4):1171–6
33. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO, III, Schechter AN, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002; 8(12):1383–9
34. Altamentova SM, Marva E, Shaklai N. Oxidative interaction of unpaired hemoglobin chains with lipids and proteins: a key for modified serum lipoproteins in thalassemia. Arch Biochem Biophys. 1997;345(1):39–46
35. Shamir R, Kassis H, Kaplan M, Naveh T, Shehadeh N. Glycemic control in adolescents with type 1 diabetes mellitus improves lipid serum levels and oxidative stress. Pediatr Diabetes 2008;9(2):104–9
36. Lai ME, Vacquer S, Carta MP, Spiga A, Cocco P, Angius F, et al. Thalassemia intermedia is associated with a proatherogenic biochemical phenotype. Blood Cells Mol Dis. 2011;46(4):294–9
37. Hartman C, Tamary H, Tamir A, Shabad E, Levine C, Koren A, et al. Hypocholesterolemia in children and adolescents with beta-thalassemia intermedia. J Pediatr. 2002;141(4):543–7
38. Chrysohoou C, Panagiotakos DB, Pitsavos C, Kosma K, Barbetseas J, Karagiorga M, et al. Distribution of serum lipids and lipoproteins in patients with beta thalassaemia major; an epidemiological study in young adults from Greece. Lipids Health Dis. 2004;3:3–8
39. Nasr MR, Abdelmaksoud AM, Abd El-Aal KS, Mabrouk NA, Ismael WM. Plasma lipid profile and lipid peroxidation in betathalassemic children. J Clin Lipidol. 2008;2(6):405–9
40. Calandra S, Bertolini S, Pes GM, Deiana L, Tarugi P, Pisciotta L, et al. Beta-thalassemia is a modifying factor of the clinical expression of familial hypercholesterolemia. Semin Vasc Med. 2004;4(3):271–8
41. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease: implications for treatment. Arch Intern Med. 1992;152(1):28–34
42. Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Miltiadous G, Goudevenos JA, et al. Altered distribution of platelet activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J. Lipid Res. 2002;43(2):256–63
43. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol. 1995;15(10):1764–73
44. Chapman MJ. Metabolic syndrome and type 2 diabetes: lipid and physiological consequences. Diab Vasc Dis Res. 2007; 4(Suppl 3):S5–8
45. Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res. 2012;53(9):1767–82
46. Persson M, Nilsson J, Nelson J, Hedblad B, Berglund G. The epidemiology of Lp-PLA2: distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 2007;190(2):388–96
47. McConnell JP, Hoefner DM. Lipoprotein-associated phospholipase A2. Clin Lab Med. 2006;26(3):679–7, vii.
48. Frasch SC, Zemski-Berry K, MurphyRC, Borregaard N, Henson PM, Bratton DL. Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A. J Immunol. 2007;178(10):6540–8
49. The Lp-PLA2 Studies Collaboration; Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, et al. Lipoproteinassociated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375(9725):1536–44
50. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997;95(1):1–4
51. Silva IT, Mello AP, Damasceno NR. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp- PLA2): a review. Lipids Health Dis. 2011;10:170
52. Butthep P, Rummavas S, Wisedpanichkij R, Jindadamrongwech S, Fucharoen S, Bunyaratvej A. Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. Am J Hematol. 2002;70(2):100–6
53. Gharagozloo M, Karimi M, Amirghofran Z. Double-faced cell-mediated immunity in β-thalassemiamajor: stimulated phenotype versus suppressed activity. Ann Hematol. 2009;88(1):21–7
54. Vaddi K, Nicolini FA, Mehta P, Mehta JL. Increased secretion of tumour necrosis factor-alpha and interferon-gamma by mononuclear leukocytes in patients with ischaemic heart disease. Relevance in superoxide anion generation. Circulation 1994; 90(2):694–9
55. Ross R. Atherosclerosis -an inflammatory disease. New Engl J Med. 1999;340(2):115–26
56. Profumo E, Buttari B, Riganò R. Oxidized haemoglobin as antigenic target of cell-mediated immune reactions in patients with carotid atherosclerosis. Autoimmun Rev. 2009;8(7):558–62
57. Boddi M, Abbate R, Chellini B, Giusti B, Solazzo V, Soft F, et al. HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. Dig Liver Dis. 2007;39(Suppl 1):S55–60
58. Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 2012;221(2):496–502
59. Caini P, Guerra CT, Giannini C, Giannelli F, Gragnani L, Petrarca A, et al. Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection. J Viral Hepat. 2007; 14(1):22–8
60. Guerra CT, Caini P, Giannini C, Giannelli F, Gragnani L, Petrarca A, et al. Effect of chronic hepatitis C virus infection on inflammatory lipid mediators. Dig Liver Dis. 2007;39(Suppl 1):S76–82
61. Antonelli A, Ferri C, Ferrari SM, Marchi S, De Bortoli N, Sansonno D, et al. N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha both are increased in patients with Hepatitis C. J Interferon Cytokine Res. 2010;30(5):359–63
62. Sayed-Ahmed L, Kotb N, El-Serogy H, El-Shazly S, Eid M. TNF-alpha and CXCL-10 correlation with insulin resistance in patients with chronic hepatitis C virus infection. Egypt J Immunol. 2010;17(1):101–11
63. González-Amaro R, García-Monzón C, García-Buey L, Moreno-Otero R, Alonso JL, Yagüe E, et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med. 1994;179(3):841–8
64. Falasca K, Ucciferri C, Dalessandro M, Zingariello P, Mancino P, Petrarca C, et al. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci. 2006;36(2):144–50
65. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol. 2005;202(2):199–211
66. Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M, et al. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J. 2009;30(1):107–15
67. Gorelick PB. Lipoprotein-associated phospholipase A2 and risk of stroke. Am J Cardiol. 2008;101(12A):34F–40F.
68. Cure MC, Tufekci A, Cure E, Kirbas S, Ogullar S, Kirbas A, et al. Low-density lipoprotein sub-fraction, carotid artery intima-media thickness, nitric oxide, and tumor necrosis factor alpha are associated with newly diagnosed ischemic stroke. Ann Indian Acad Neurol. 2013;16(4):498–503.